Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1171 to 1185 of 1260 results for heart OR cardi* OR arrythmia

  1. What is the most clinically and cost-effective tool for diagnosing peripheral arterial disease in people with diabetes?

    notes(if applicable) People with diabetes are at higher risk of cardiovascular events and foot problems such as diabetic neuropathy...

  2. How can fetuses at risk of intrauterine death be identified in women with diabetes?

    Conventional tests of fetal wellbeing (umbilical artery Doppler ultrasound, cardiotocography and other biophysical tests) have been...

  3. Rehabilitation after traumatic injury (NG211)

    This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.

  4. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

  5. The social care guidance manual (PMG10)

    The social care guidance manual

  6. Guide to the methods of technology appraisal 2013 (PMG9)

    Guide to the methods of technology appraisal 2013

  7. 1.4 million more people at risk of severe COVID-19 to have access to antiviral Paxlovid

    A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive following updated NICE final draft guidance published today (11 January 2024).

  8. Millions of people with cardiovascular disease could benefit from a new cholesterol treatment target recommendation

    Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.

  9. NICE draft updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  10. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  11. NICE says non-invasive weight loss procedure can be an option to treat obesity

    A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.

  12. NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes

    Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment option recommended by NICE

  13. Technologies offering monitoring from home in virtual wards recommended for people with an acute respiratory infection

    People with an acute respiratory infection (ARI) could be monitored from their own homes using technology platforms that will feedback vital information on their condition to clinical staff, NICE has said in draft guidance.

  14. NHS at 75

    Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.

  15. First treatment to target heart condition set to benefit thousands as NICE draft guidance approves NHS use

    NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.